CSIC has developed an immunochemical method for diagnosis of infections produced by Pseudomonas aeruginosa targeting the main signaling molecules of the pqs Quorum Sensing system. The immunoassay is fast and efficient, with low LOD and adaptable to point-of care devices.
Industrial partners from the pharmaceutical or diagnostics industry are being sought to collaborate through a patent licence agreement.
Detection of the main alkylquinolones of pqs Quorum Sensing system of Pseudomonas aeruginosa Pseudomonas aeruginosa is an opportunistic pathogen responsible for a huge number of infections, especially in immunocompromised patients, and extremely life-threatening if not appropriately diagnosed and treated at the early stage. Traditional microbiology testing can take 24-48h to determine the causative agent of an infection, and other methods, such as PCR, although much faster require highly trained staff and expensive equipment only available in specialized facilities. This fact, results in prescription and misuse of broadspectra antibiotics, contributing to the generation of resistance. The close connection between the release of signaling molecules of the Quorum Sensing of P. aeruginosa (QS) and the virulence of infection make these molecules as good biomarkers for detection of infections caused by P. aeruginosa. Here, is presented the first in vitro immunodiagnostic ELISA test for identification and quantification of the main signaling molecules from the pqs QS system. The assay is able to quantify PQS, HHQ and HQNO alkylquinolones in the low nM range, even in complex clinical samples.
P. aeruginosa bacteria in mucosa of patients with cystic fibrosis. The method is able to differentiate chronic from acute stage of infection.
Main innovations and advantages
· Development of a robust, high sensitive, accurate, low-cost, simple and rapid microplate-based · ELISA test for analyzing clinical samples.